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Abstract 
Vulvovaginal candidiasis (VVC) affects a significant number of women, especially in working age. In an estimated 75% of 
women an episode of acute vulvovaginal candidiasis occurs during lifetime and another 5 – 10% of women develop recurrent 
vulvovaginal candidiasis (RVVC). This is mainly characterized by intense burning, itching, pain, abnormal discharge, 
dyspareunia. Immune response to candidiasis is both cellular (CMI) (natural protection mechanisms) and humoral (antibody 
production). Understanding the principles of immunity in candidiasis is also important for development of candida vaccines. 
CANDIVAC contains lyophilized Candida lysate (C. albicans, C. krusei, C. glabrata) together with immunostimulatory bacterial 
strain of Propionibacterium acnes. The product is taken orally in capsules for 10 days followed by a 20-day pause. It is 
administered for 3 to 6 months. The product has been tested in a total of 75 women at the age of 18 – 45 years. In these women at 
least 4 episodes of vulvovaginal candidiasis have been microscopically or laboratory diagnosed during the last 12 months. 
Following CANDIVAC administration, statistically significant changes occurred in the evaluation of subjective and some 
objective criteria. The most important marker of product efficiency is a significant reduction in recurrence compared to the recent 
state. This criterion has a fundamental importance in patient satisfaction. Before medication the patients suffered from at least 4 
attacks, while after medication an attack occurred in only 31% of women and more than 2 attacks in only 3% of treated women. 
Compromised balance of immune system plays a major role in recurrent vulvovaginal candidiasis. Specific oral product 
CANDIVAC, prepared from the most common strains of yeast infections, supports immune mechanisms, ensuring resistance of 
the human organism against yeasts. Its administration significantly prolongs remission, leads to a reduction in application of 
antimycotics and also changes properties of cellular and humoral immunity in medicated patients. 
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Introduction 
Vulvovaginal candidiasis (VVC) and recurrent vulvovaginal candidiasis caused by Candida type of bacteria are a 
significant public health problem affecting a large number of otherwise healthy women. That is why the 
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immunotherapy and vaccines are subject to medical research1, 2. CANDIVAC medication is a lysate of Candida 
albicans, C. krusei, C. glabrata and Propionibacterium acnes. This product is patented in the EU and in the USA3. 
A clinical study verified its effects in female patients. This study is subject to further analysis in this paper4. 
 
Methodology 
The study included 75 women aged 18 - 45 (mean age 31.2) from 5 gynaecology outpatient clinics who had 
experienced at least 4 episodes of mycotic vulvovaginitis in the last 12 months and received microscopy-based or 
laboratory-based diagnosis. At the moment of inclusion a participant had to be free of acute inflammation of internal 
genitalia, and of bacterial vaginosis. 
After meeting all the inclusion criteria the female participants started using CANDIVAC®. CANDIVAC® contains 
lyophilized inactivated strain of Candida albicans, Candida glabrata and Candida krusei and the 
immunostimulating strain of Propionibacterium acnes. Total volume of the lyophilized bacterial lysate is 5 mg, 
vehiculum volume is 195 mg in 1 capsule. One package contains 30 capsules of 200 mg. CANDIVAC® was 
administered orally 1x daily on empty stomach for 10 days followed by a 20-day pause period. This dosage model 
was followed for 6 months. 
Assessments were performed just before inclusion of the female participants into the study and repeated after 6 
months (cessation of planned medication) and after 9 and 12 months since the study initiation. The study was 
completed by 68 women (7 were excluded). 
 
Results 
a) Subjective criteria 
There were some statistically significant changes during evaluation of subjective criteria (Tab. 1). 
b) Lactobacilliary gradient (LG) values and number of leukocytes in the visual field 
Lactobacilliary gradient (LG) values and number of leukocytes in the visual field remained without any 
changes (Tab. 2). 
c) Vaginal yeast colonisation 
The number of vaginal yeast colonisations declined (cultivation and microscopy). (Tab. 3). 
d) The progress of relapsing vulvovaginal candidiasis during the study 
During the study there was a decline in vulvovaginal candidiases (Tab. 4). 
 
Tab. 1, Evaluation of subjective complications in patients using Total Symptom Score (TSS) 
A - Inclusion criteria 
Type of complication None Mild Medium Severe 
Discharge 0 1 2 3 
Itching 0 1 2 3 
Burning 0 1 2 3 
Total number above 5 indicates acute inflammation and patient cannot be included into the study 
 
B - Progress of subjective complications index in patients (TSS) during the study 
Assessments  Total Symptom Score 
Initial 2.4 
After 6 months 0.7 
After 9 months 0.9 
After 12 months 1.4 
 
Tab. 2, Evaluation of lactobacilliary gradient (LG) and number of leukocytes (LEU) in the visual field during the study 
 Study lasted (months) 
 0 6 9 12 
LG I 41.2 % 44.1 % 39.7 % 39.7 % 
LG II 51.1 % 51.4 % 57.4 % 52.9 % 
LG III 7.4 % 4.4 % 2.9 % 7.4 % 
LEU ≤ 10 92.6 % 94.1 % 95.6 % 94.1 % 
LEU >  7.4 % 5.9 % 4.4 % 5.9 % 
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Tab. 3, Progress of vaginal yeast colonisation during the study 
 Study lasted (months) 
 0 6 9 12 
Cultivation 55.9% 36.8% 36.8% 39.7% 
Microscopy 39.7% 25.0% 20.6% 22.1% 
 
Tab. 4, Progress of relapsing vulvovaginal candidiasis during the study (prior to study at least 4 episodes in each  patient per year!) 
Assessment Frequency of relapses Total 1 times 2 times Multiple times 
After 6 months 10 (15 %) 9 1 0 
After 9 months 16 (24 %) 11 4 1 
After 12 months 21 (31 %) 12 6 3  
 
Discussion 
Recurrent vulvovaginal candidiasis presents a transient secondary immunodeficiency or reduction of non-specific 
natural immunity. Immunomodulation may help; it aims to put the immunocompetent cells in a state of emergency. 
The most natural and safest immunomodulators are lysates that contain mixture of required specific antigens. The 
best way to attain optimal immunomodulatory effect is to administer lysates in order to reach the epithelial cells of 
mucosa. Body mucosa is accompanied by immunocompetent tissue. In the lymphoid tissue, there are essential 
immune processes taking place and the immune reactions then spread to the whole body. Therefore, oral 
administration of yeast lysates is irreplaceable.   
 
Conclusion 
During relapsing vulvovaginal candidiases the balance of immunity system is impaired. Patented, specific, oral and 
immunostimulating product CANDIVAC enhances immunity mechanisms that ensure resilience to yeast, and it has 
been prepared from the most common strains of yeast infections affecting vulvovaginal system. Its administration 
was proved to prolong the relapse period of vulvovaginal conditions, it leads to reduction of antimycotic agents and 
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